Home/Pipeline/DPM-1003

DPM-1003

Rett Syndrome

Phase 1Active

Key Facts

Indication

Rett Syndrome

Phase

Phase 1

Status

Active

Company

DepYmed

About DepYmed

DepYmed is a clinical-stage biotech leveraging a proprietary platform to develop selective inhibitors of protein tyrosine phosphatase 1B (PTP1B) and copper chelators. The company is advancing two orally bioavailable small molecules into clinical trials, with its lead asset, DPM-1003 for Rett Syndrome, having recently received FDA clearance to initiate a Phase 1 trial. With a focus on rare diseases and oncology, DepYmed is backed by venture capital and led by a team with deep expertise in drug development and phosphatase biology.

View full company profile

Therapeutic Areas

Rett Syndrome Oncology Wilson Disease Metabolic Diseases Neurodegenerative Diseases

Other Rett Syndrome Drugs

Drug	Company	Phase	Status
NTI164	Neurotech International	Phase 2	Active
RTT1	Grann Pharmaceuticals	Pre-clinical	Active
NEX-1 / NEX-2	Nexien BioPharma	Pre-clinical / Phase 1	Active
KIT-13	NeuroCores	Pre-clinical	Active
ExoEdit® for Rett Syndrome	Evox Therapeutics	Pre-clinical	Active
RVL-001 (vorinostat)	Unravel Biosciences	Clinical Trial Initiated	Active
Rett Syndrome Program	Herophilus	Discovery	Active
Glutamate Modulator for Rett Syndrome	Numedicus	Licensed/Orphan Designation	Active
TTI-0102	Thiogenesis Therapeutics	Phase 1	Planned
DAYBUE® (trofinetide)	Neuren Pharmaceuticals	Approved	Commercial
TSHA-102	Taysha Gene Therapies	Phase 1/2	Active (Pivotal-Enabling)
Sarizotan	Newron Pharmaceuticals	Phase III	Discontinued